AngioDynamics Files 8-K on Financials

Ticker: ANGO · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1275187

Angiodynamics Inc 8-K Filing Summary
FieldDetail
CompanyAngiodynamics Inc (ANGO)
Form Type8-K
Filed DateJan 8, 2025
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-results, 8-k

Related Tickers: ANGI

TL;DR

ANGI filed an 8-K on Jan 8, 2025, covering financial results. Details to follow.

AI Summary

On January 8, 2025, AngioDynamics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or significant events were detailed in the provided excerpt.

Why It Matters

This filing provides an update on AngioDynamics' financial performance and operational results, which is crucial for investors to assess the company's current health and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting financial results and does not indicate any immediate or significant risks.

Key Players & Entities

  • AngioDynamics, Inc. (company) — Registrant
  • January 8, 2025 (date) — Date of earliest event reported
  • 14 Plaza Drive, Latham, New York 12110 (address) — Principal Executive Offices
  • 518-795-1400 (phone_number) — Registrant's telephone number

FAQ

What specific financial results are being reported in this 8-K filing?

The provided excerpt indicates the filing concerns 'Results of Operations and Financial Condition' but does not detail specific financial figures.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is January 8, 2025.

What is the principal executive office address for AngioDynamics, Inc.?

The principal executive offices are located at 14 Plaza Drive, Latham, New York 12110.

What is the telephone number for AngioDynamics, Inc.?

The registrant's telephone number, including area code, is (518) 795-1400.

What are the main items covered by this 8-K filing?

This 8-K filing covers Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits.

Filing Stats: 976 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2025-01-08 07:00:28

Key Financial Figures

  • $0.01 — registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select

Filing Documents

02 – Results of Operations and Financial Condition

Item 2.02 – Results of Operations and Financial Condition. On January 8, 2025, AngioDynamics, Inc. ("AngioDynamics") issued a press release announcing financial results for the fiscal second quarter ended November 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1. The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 – Regulation FD Disclosure

Item 7.01 – Regulation FD Disclosure. Presentation slides discussing AngioDynamics and its fiscal second quarter ended November 30, 2024 are furnished herewith as Exhibit 99.2. The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.

Forward-Looking Statements

Forward-Looking Statements This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of produ

01 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated January 8, 2025. 99.2 Presentation, dated January 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: January 8, 2025 By: /s/ Lawrence T. Weiss Name: Lawrence T. Weiss Title: Senior Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.